Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04052880 · ClinicalTrials.gov registry record · Phase 2

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

A Phase 2 study of Newly Diagnosed Multiple Myeloma, sponsored by Larysa Sanchez.

Active
Registry status
Phase 2
Development phase
17
Enrollment target
1
Study location

NCT04052880: Active Phase 2 study of Newly Diagnosed Multiple Myeloma, sponsored by Larysa Sanchez.

NCT04052880 is a Phase 2 study of Newly Diagnosed Multiple Myeloma that is active but no longer recruiting, run by Larysa Sanchez. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04052880, a Phase 2 study of Newly Diagnosed Multiple Myeloma, is active but no longer recruiting, sponsored by Larysa Sanchez.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the study, subjects will be monitored closely for adverse events, laboratory abnormalities, and clinical response.

Primary Outcome

≥ VGPR rate after 8 cycles of therapy, defined as the proportion of subjects who have achieved VGPR or better, according to the IMWG criteria.

Conditions Studied

Newly Diagnosed Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Daratumumab
  • DRUG Bortezomib
  • DRUG Ixazomib

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2019-10-24
Est. Completion 2026-05
Phase Phase 2
Larysa Sanchez

2 total trials

What the registry record for NCT04052880 still lists

NCT04052880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Newly Diagnosed Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.

NCT04052880 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04052880 about?

NCT04052880 is a clinical study titled "Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM". This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, disconti...

What is the current status of trial NCT04052880?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2019-10-24. Estimated completion is 2026-05.

What conditions does trial NCT04052880 study?

This clinical trial studies the following conditions: Newly Diagnosed Multiple Myeloma.

What interventions are being tested in trial NCT04052880?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Bortezomib (DRUG), Ixazomib (DRUG).

Who is sponsoring clinical trial NCT04052880?

This trial is sponsored by Larysa Sanchez, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04052880 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Newly Diagnosed Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04052880's enrollment target sits among peer trials

17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04052880, the US trial registry maintained by the National Library of Medicine. NCT04052880 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.